Skip to main content

Ketoconazole (Topical) (Monograph)

Brand names: Extina, Nizoral, Nizoral A-D, Xolegel
Drug class: Azoles

Medically reviewed by Drugs.com on Jun 21, 2024. Written by ASHP.

Introduction

Antifungal; azole (imidazole derivative).1 3 4 5 6 11 23 32 72 105 106 110

Uses for Ketoconazole (Topical)

Dermatophytoses

Treatment of tinea corporis, tinea cruris, and tinea pedis caused by Epidermophyton floccosum, Trichophyton mentagrophytes, or T. rubrum.1 2 25 27 28 56 58 59 60 61 62 66 78 79 110

A drug of first choice for topical treatment of tinea corporis or tinea cruris.81 85 Oral antifungals preferred when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised or has coexisting disease.80 81 82 83 84

Treatment of tinea manuum† [off-label] caused by Trichophyton2 25 58 59 60 61 62 and tinea corporis caused by Microsporum† [off-label].2 25 59

Cutaneous Candidiasis

Treatment of cutaneous candidiasis caused by Candida albicans.1 2 25 58 59 67 68 69 110

Pityriasis (Tinea) Versicolor

Treatment of pityriasis (tinea) versicolor caused by or presumed to be caused by Malassezia furfur (Pityrosporum orbiculare or P. ovale).1 2 25 26 63 72 97 110

Seborrheic Dermatitis and Dandruff

Treatment of seborrheic dermatitis, including seborrheic dermatitis of the scalp.1 12 42 43 44 67 71 73 76 98 99 101 103 105 106 107 108 109

Self-medication (OTC use) for reduction of flaking, scaling, and itching associated with dandruff.74 75 77 99 100 101 102 104

Ketoconazole (Topical) Dosage and Administration

Administration

Topical Administration

Apply topically to skin as a 2% cream,1 110 foam,106 gel,105 or shampoo.72 97

Apply topically to hair and scalp as a 1% shampoo.100 104 Also has been applied topically to hair† [off-label] and scalp† [off-label] as a 2% shampoo.76 98 99 101 103

Cream, foam, gel, and shampoo are for external use only.1 72 104 105 106 Do not apply to eyes1 72 104 105 106 and do not administer orally105 106 or intravaginally.56 57 105 106

If contact with eyes, mouth, or vagina occurs, rinse thoroughly with water.104 106

When using the 2% foam, hold the can containing the foam upright and spray a small amount into the cap of the can or other cool surface.106 Do not dispense foam directly onto affected areas or onto hands since the foam will begin to melt immediately on contact with warm skin.106 If fingers are warm, rinse them in cold water and dry before handling the foam.106 Using the fingertips, gently massage small amounts of foam onto affected areas until the foam disappears and entire affected area has been treated.106

When using the 2% gel, do not apply sunscreen or cosmetics to the affected area until at least 20 minutes after application of the gel.105 Do not wash the affected area for at least 3 hours after application of the gel.105

Avoid fire, flame, and/or smoking during and immediately after application of 2% foam or gel.105 106 (See Flammability under Cautions.)

Dosage

Pediatric Patients

Topical Seborrheic Dermatitis in Children ≥12 Years of Age

2% gel: Apply to affected areas once daily for 2 weeks.105 107 108

2% foam: Apply to affected areas twice daily for 4 weeks.106 109

Dandruff in Children ≥12 Years of Age
Topical

1% shampoo: For self-medication, apply to wet hair, lather, and rinse thoroughly; then repeat application, lathering, and rinsing.104 Use every 3 or 4 days for up to 8 weeks as needed or as directed by a clinician.104 Thereafter, use as needed to control dandruff.104

Adults

Dermatophytoses
Tinea Corporis or Tinea Cruris
Topical

2% cream: Apply and rub gently into affected and surrounding area of skin once or twice daily for 2 weeks.1 2 25 58 59 62 110 There is some evidence that twice-daily regimen may occasionally be more effective than once-daily regimen.25 62 If clinical improvement does not occur after treatment, reevaluate diagnosis.1 110

Tinea Pedis
Topical

2% cream: Apply and rub gently into affected and surrounding area of skin once or twice daily for 6 weeks.1 2 60 66 79 110 If clinical improvement does not occur after treatment, reevaluate diagnosis.1 110

Moccasin-type (dry-type) tinea pedis may require more prolonged therapy.66 79

Cutaneous Candidiasis
Topical

2% cream: Apply and rub gently into affected and surrounding area of skin once or twice daily for 2 weeks.1 2 25 58 59 110 If clinical improvement does not occur after treatment, reevaluate diagnosis.1 110

Pityriasis (Tinea) Versicolor
Topical

2% cream: Apply and rub gently into affected and surrounding area of skin once daily for 2 weeks.1 110 If clinical improvement does not occur after treatment, reevaluate diagnosis.1 110

2% shampoo: Apply to damp skin of the affected area and a wide margin surrounding this area and lather; after 5 minutes, rinse with water.72 A single application should be sufficient,72 97 although once-daily application for 3 days also has been used.97

Seborrheic Dermatitis
Topical

2% cream: Apply and rub gently into affected areas twice daily1 12 42 43 44 67 71 for 4 weeks or until clinical clearing.1 12 42 43 44 71

2% foam: Apply and gently massage into affected areas twice daily for 4 weeks.106 109

2% gel: Apply to affected areas once daily for 2 weeks.105 107 108

2% shampoo: For seborrheic dermatitis of the scalp† [off-label], has been used to wash the hair and scalp 2 or 3 times weekly for 2–4 weeks.76 98 99 101 After a response was obtained, has been used once weekly every other week to prevent relapse.98

Dandruff
Topical

1% shampoo: For self-medication to control flaking, scaling, and itching associated with dandruff, apply to thoroughly wet hair, lather and rinse thoroughly; then repeat application, lathering, and rinsing.104 Use every 3 or 4 days for up to 8 weeks as needed or as directed by a clinician.104 Thereafter, use as needed to control dandruff.104

2% shampoo: For treatment of dandruff†, has been used to wash the hair and scalp 2 or 3 times weekly for 2–4 weeks.76 98 99 101 After a response was obtained, has been used once weekly every other week to prevent relapse.98

Detailed Ketoconazole topical dosage information

Cautions for Ketoconazole (Topical)

Contraindications

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Contact dermatitis reported following topical application of ketoconazole or other imidazole-derivative azole antifungals.61 89 90 91 92 93 94 110

If a reaction suggesting sensitivity or chemical irritation occurs (e.g., rash), discontinue the drug.1 72 104 105 106 110

Possible cross-sensitization among the imidazole derivatives.89 90 91 92 93 94

Sulfite Sensitivity

Some formulations of the 2% cream contain sodium sulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.110 Overall prevalence of sulfite sensitivity in the general population is unknown, but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.110

General Precautions

Systemic Adverse Effects

Although hepatotoxicity, decreased testosterone concentrations, and decreased ACTH-induced corticosteroid concentrations have been reported with oral ketoconazole,32 105 110 these adverse effects have not been reported with topical ketoconazole105 110 and are unlikely since the drug does not appear to be appreciably absorbed following topical application to skin.2 56 57

Flammability

2% foam and gel are flammable.105 106 Avoid fire, flame, and/or smoking during and immediately after application of foam or gel.105 106 (See Storage under Stability.)

Specific Populations

Pregnancy

Category C.1 72 105 106 110

2% cream, foam, gel, or shampoo: Use during pregnancy only when potential benefits justify possible risks to the fetus.1 72 105 106 110

1% shampoo: Pregnant women considering self-medication should consult a clinician before using the preparation.104

Lactation

Not known whether ketoconazole distributed into milk following topical application.1 105 106 110

2% cream: Discontinue nursing or the cream.1 110

2% foam, gel, or shampoo: Use with caution.72 105 106

1% shampoo: Nursing women considering self-medication should consult clinician before using the preparation.104

Pediatric Use

2% cream: Safety and efficacy not established in children;1 110 has been used without unusual adverse effect in children 2 days to 12 years of age.15 17

2% foam: Safety and efficacy not established in children <12 years of age.106

2% gel: Safety and efficacy not established in children <12 years of age.105

1% shampoo: Safety and efficacy for self-medication not established in children <12 years of age.104

2% shampoo: Safety and efficacy not established in children.72

Common Adverse Effects

2% cream: Local reactions at application site (severe irritation, pruritus, stinging).1 2 25 26 58 59 60 61 110

2% foam: Application site reactions (e.g., burning).106 109

2% gel: Application site reactions (e.g., burning), headache.105 107 108

2% shampoo: When applied to the skin, pruritus, application site reaction, dry skin.72 When applied to scalp, increased hair loss, irritation, abnormal hair texture, loss of hair curl in patients with permanently waved (“permed”) hair, scalp pustules, dry skin, pruritus, oiliness or dryness of the hair and scalp.72

Drug Interactions

No formal drug interaction studies to date.105

Ketoconazole (Topical) Pharmacokinetics

Absorption

Bioavailability

Ketoconazole does not appear to be appreciably absorbed systemically following topical application to skin or scalp.1 2 24 25 56 63 72 105 106 110

2% cream: Topical application to chest, back, and arms of healthy adults with intact skin does not result in detectable blood concentrations.1 2 24 110 Following topical application in vitro in a skin model, ketoconazole was retained in the stratum corneum and the boundary of the stratum corneum and stratum granulosum for up to 16 hours.56 63

2% foam: Topical application of 3 g twice daily for 4 weeks in patients with moderate to severe seborrheic dermatitis resulted in plasma ketoconazole concentrations <6 ng/mL in 75% of patients; maximum plasma concentration was 11 ng/mL.106

2% gel: Topical application once daily for 2 weeks (0.05-3.47 g daily) in patients with severe seborrheic dermatitis (1–14% of body surface area) resulted in mean peak plasma concentrations of 1.35 ng/mL on day 7 and 0.8 ng/mL on day 14.105

2% shampoo: Chronic use of 2% shampoo (4–10 times weekly for 6 months, 2–3 times weekly for 3–26 months) did not result in detectable plasma concentrations.72

Small amounts of ketoconazole are absorbed systemically when the drug is administered intravaginally.24

Distribution

Extent

Not known whether ketoconazole distributed into milk following topical application of 2% cream, foam, gel, or shampoo.1 105 106 110

Stability

Storage

Topical

2% Cream

20–25°C110 or 15–30°C,1 depending on manufacturer.

2% Foam

20–25°C; do not refrigerate or freeze.106

Flammable; do not store in direct sunlight and do not expose to heat or temperatures >49°C.106 Do not puncture and/or incinerate container.106

2% Gel

25°C (may be exposed to 15–30°C).105

1% Shampoo

2–30°C; protect from light and freezing.104

2% Shampoo

≤25°C; protect from light.72

Actions and Spectrum

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Ketoconazole

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Cream

2%*

Ketoconazole Cream

Foam

2%

Extina

Stiefel

Gel

2%

Xolegel

Barrier Therapeutics

Shampoo

1%

Nizoral A-D

McNeil

2%*

Ketoconazole Shampoo,

Nizoral

Ortho-McNeil

AHFS DI Essentials™. © Copyright 2025, Selected Revisions July 1, 2009. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Taro Pharmaceuticals. Ketoconazole cream, 2% prescribing information. Brampton, Ontario; 2002 Nov.

2. Cauwenbergh GF, Degreef H, Verhoeve LS. Topical ketoconazole in dermatology: a pharmacological and clinical review. Mykosen. 1984; 27:395-401. https://pubmed.ncbi.nlm.nih.gov/6090895

3. Van den Bossche H, Ruysschaert JM, Defrise-Quertain F et al. The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol. 1982; 31:2609-17. https://pubmed.ncbi.nlm.nih.gov/6291539

4. Shadomy S, Espinel-Ingroff A, Kerkering TM. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia. 1984; 22:7-15. https://pubmed.ncbi.nlm.nih.gov/6322364

5. Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984; 25:450-4. https://pubmed.ncbi.nlm.nih.gov/6375555 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC185550/

6. Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984; 26:5-9. https://pubmed.ncbi.nlm.nih.gov/6089654 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179904/

7. Bergan T, Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983; 29:104-10. https://pubmed.ncbi.nlm.nih.gov/6301773

8. Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984; 30:244-7. https://pubmed.ncbi.nlm.nih.gov/6086246

9. Cohen J. Antifungal chemotherapy. Lancet. 1982; 2:532-7. https://pubmed.ncbi.nlm.nih.gov/6125688

10. Dixon D, Shadomy S, Shadomy HJ et al. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis. 1978; 138:245-8. https://pubmed.ncbi.nlm.nih.gov/681800

11. Graybill JR, Craven PC. Antifungal agents used in systemic mycoses: activity and therapeutic use. Drugs. 1983; 25:41-62. https://pubmed.ncbi.nlm.nih.gov/6297871

12. Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with topical ketoconazole. Lancet. 1984; 2:1271-2. https://pubmed.ncbi.nlm.nih.gov/6150296

13. Donadini A. The combination of an anti-inflammatory steroid, an antibacterial agent, and an antifungal in the treatment of outpatients with skin diseases of uncertain aetiology. Curr Ther Res Clin Exp. 1985; 37:478-84.

14. Cristiani T. Experience with the combination of an anti-inflammatory steroid, an antibacterial agent and an antimycotic agent in the topical treatment of skin diseases of various origins. Curr Ther Res Clin Exp. 1985; 37:225-31.

15. Minak G, Beverini S. Treatment of forms of infantile dermatitis with a multi-purpose drug combination. Curr Ther Res Clin Exp. 1984; 36:1198-1202.

16. Berardesca E. Combination treatment of skin diseases of mixed aetiology with an anti-inflammatory steroid, an antibacterial agent, and an antifunal. Curr Ther Res Clin Exp. 1985; 37:791-6.

17. Trabacco M. Treatment of dermatological manifestations in infants with a multivalent combination. Curr Ther Res Clin Exp. 1985; 37:784-9.

18. Pazzaglia A. Clinical results obtained with a combination of an anti-inflammatory steroid, an antibacterial agent and an antifungal in dermatological outpatient practice. Int J Clin Pharmacol Ther Toxicol. 1985; 23:367-72. https://pubmed.ncbi.nlm.nih.gov/4030166

19. Gini M. Use of a combination of an anti-inflammatory corticosteroid, an antibacterial agent and an antifungal in the local post-operative treatment of cutaneo-mucosal diseases following cryosurgery. Int J Clin Pharmacol Ther Toxicol. 1985; 23:373-5. https://pubmed.ncbi.nlm.nih.gov/4030167

20. Pellerano S. Use of a combination of an anti-inflammatory steroid, an antibacterial agent and an antifungal in dermatological practice. Int J Clin Pharmacol Ther Toxicol. 1985; 23:215-8. https://pubmed.ncbi.nlm.nih.gov/3888858

21. Borgers M, Van den Bossche H, De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am J Med. 1983; 74(Suppl 1B):2-8. https://pubmed.ncbi.nlm.nih.gov/6295147

22. Heel RC. In vitro and in vivo activity. In: Levine HB, ed. Ketoconazole in the management of fungal disease. New York: Adis Press; 1982:57-66.

23. Janssen Pharmaceutica. Product information form for ketoconazole. Piscataway, NJ; 1986 Feb.

24. Rawlins M. Systemic absorption of ketoconazole 2% cream. Janssen clinical research report N 31403. Piscataway, NJ; 1982 Sep.

25. Janssen Pharmaceutica. Ketoconazole 2% cream: systemic absorption, skin irritancy, and therapeutic effectiveness in animals and man. A review of the available data up to April 1983. Research report No. N 31597. Piscataway, NJ; 1983 Apr.

26. Savin RC. Double-blind comparison of 2% ketoconazole cream (R 41,400) and placebo in the treatment of tinea versicolor: Janssen Pharmaceutica clinical research report N 31513. Piscataway, NJ; 1983 Mar.

27. Taplin D, Carmargo G. Double-blind comparison of 2% ketoconazole cream (R 41,400) and placebo in the treatment of tinea corporis and tinea cruris. Janssen Pharmaceutica clinical research report No. N 31514. Piscataway, NJ; 1983 Mar.

28. Taplin D, Carmargo G. Double-blind comparison of 2% ketoconazole cream (R 41,400/98) and placebo in the treatment of fungal infections of the feet. Janssen Pharmaceutica clinical research report No. N 31511. Piscataway, NJ; 1983 Mar.

29. Torres MA, Mohamed J, Cavazos-Adame H et al. Topical ketoconazole for fungal keratitis. Am J Ophthalmol. 1985; 100:293-8. https://pubmed.ncbi.nlm.nih.gov/4025470

30. Komadina TG, Wilkes DI, Shock JP et al. Treatment of Aspergillus fumigatus keratitis in rabbits with oral and topical ketoconazole. Am J Ophthalmol. 1985; 99:476-9. https://pubmed.ncbi.nlm.nih.gov/3872596

31. O’Day DM, Ray WA, Head WS et al. Influence of the corneal epithelium on the efficacy of topical antifungal agents. Invest Ophthalmol Vis Sci. 1984; 25:855-9. https://pubmed.ncbi.nlm.nih.gov/6329991

32. Teva Pharmaceuticals. Ketoconazole tablets prescribing information. Sellersville, PA; 2003 Nov.

34. Pye GW, Marriott MS. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982; 20:325-9. https://pubmed.ncbi.nlm.nih.gov/6760419

35. Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984; 14:105-14. https://pubmed.ncbi.nlm.nih.gov/6094418

36. Odds FC. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 1980; 6:749-61. https://pubmed.ncbi.nlm.nih.gov/7440468

37. Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs. 1986; 31:29-51. https://pubmed.ncbi.nlm.nih.gov/3510114

38. Pottage JC Jr, Kessler HA, Goodrich JM et al. In vitro activity of ketoconazole against herpes simplex virus. Antimicrob Agents Chemother. 1986; 30:215-9. https://pubmed.ncbi.nlm.nih.gov/3021048 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC180521/

39. Ford GP, Ive FA, Midgley G. Pityrosporum folliculitis and ketoconazole. Br J Dermatol. 1982; 107:691-5. https://pubmed.ncbi.nlm.nih.gov/6293529

40. Van Cutsem J. The antifungal activity of ketoconazole. Am J Med. 1982; 74(Suppl 1B):9-15.

41. Anon. Boxed warning added to ketoconazole label. FDA Drug Bull. 1983; 13:15-6. https://pubmed.ncbi.nlm.nih.gov/6311655

42. Skinner RB Jr, Zanolli MD, Noah PW et al. Seborrheic dermatitis and acquired immunodeficiency syndrome. J Am Acad Dermatol. 1986; 14:147-8. https://pubmed.ncbi.nlm.nih.gov/2936769

43. Skinner RB Jr, Noah PW, Taylor RM et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol. 1985; 12(15 Part 1):852-6. https://pubmed.ncbi.nlm.nih.gov/3159759

44. Skinner RB Jr, Noah PW, Zanolli MD et al. The pathogenic role of microbes in seborrheic dermatitis. Arch Dermatol. 1986; 122:16-7. https://pubmed.ncbi.nlm.nih.gov/2935085

45. Faergemann J. In vitro and in vivo activities of ketoconazole and itraconazole against Pityrosporum orbiculare. Antimicrob Agents Chemother. 1984; 26:773-4.

46. Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia. 1984; 22:53-63. https://pubmed.ncbi.nlm.nih.gov/6322363

47. Tavitian A, Raufman JP, Rosenthal LE et al. Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology. 1986; 90:443-5. https://pubmed.ncbi.nlm.nih.gov/3510145

48. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother. 1986; 17:269-79. https://pubmed.ncbi.nlm.nih.gov/3516967

49. Beggs WH, Andrews FA, Sarosi GA. Minireview: action of imidazole-containing antifungal drugs. Life Sci. 1981; 28:111-8. https://pubmed.ncbi.nlm.nih.gov/7019609

50. Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev Infect Dis. 1980; 2:520-34. https://pubmed.ncbi.nlm.nih.gov/7003674

51. Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981; 76:438-41. https://pubmed.ncbi.nlm.nih.gov/7017013

52. Beggs WH. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother. 1984; 25:316-8.

53. Beggs WH. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985; 16:397-9. https://pubmed.ncbi.nlm.nih.gov/3902762

54. Minagawa H, Kitaura K, Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother. 1983; 23:105-7.

55. Sud IJ, Feingold DS. Heterogeneity of action among antimycotic imidazoles. Antimicrob Agents Chemother. 1981; 20:71-4. https://pubmed.ncbi.nlm.nih.gov/6269485 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181635/

56. Janssen Pharmaceutica, Titusville, NJ: Personal communication.

57. Reviewers’ comments (personal observations); 1986 Sep.

58. Meisel C. Single-blind, side-to-side comparison of ketoconazole 2% cream and clotrimazole 1% cream in 8 patients with superficial mycotic infections. Janssen Pharmaceutica clinical research report No. N 31398. Piscataway, NJ; 1983 Mar.

59. Qadripur SA, Hellgren L, Gjertsen BT et al. Double-blind comparison of ketoconazole 2% cream and clotrimazole 1% cream in the treatment of superficial fungal infections: an international multicenter study. Janssen Pharmaceutica clinical research report No. N 31402. Piscataway, NJ; 1983 Mar.

60. Swanson NA. A double-blind randomized comparative trial of once- and twice-daily ketoconazole 2% cream and placebo in the treatment of tinea pedis. Janssen Pharmaceutica clinical research report. Piscataway, NJ; 1984 Sep.

61. Jolly HW, Greer D. Double-blind comparison of two doses of 2% ketoconazole cream (R41,400) in the treatment of chronic and acute tinea pedis. Janssen Pharmaceutica clinical research report No. N 31512. Piscataway, NJ; 1983 Mar.

62. Satriano RC. Ketoconazole 2% cream: an open comparison between one and two daily applications in patients with dermatophyte infections of the skin. Janssen Pharmaceutica clinical research report No. N 31400. Piscataway, NJ; 1983 Feb.

63. Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol. 1986; 15:500-3. https://pubmed.ncbi.nlm.nih.gov/3760275

64. Smith KJ, Warnock DW, Kennedy CT et al. Azole resistance in Candida albicans. J Med Vet Mycol. 1986; 24:133-44.

65. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use; warning statements. [21 CFR Part 201] Fed Regist. 1986; 51:43900-5.

66. Greer D, Jolly HW. Comparative trial of a two-dosage schedule of ketoconazole 2% cream for the treatment of tinea pedis. J Am Acad Dermatol. 1987; 17:53-6. https://pubmed.ncbi.nlm.nih.gov/3301923

67. Smith EB. Ketoconazole 2% cream. Semin Dermatol. 1987; 6:62-5.

68. Greer D, Jolly HW. Topical ketoconazole treatment of cutaneous candidiasis. J Am Acad Dermatol. 1988; 4(Part 1):748-50.

69. Janssen Pharmaceutica. Ketoconazole 2% cream once daily in the treatment of cutaneous candidiasis: a summary of four double-blind placebo-controlled studies. Clinical summary report R 41400. Piscataway, NJ; 1986 Jul.

70. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol. 1987; 116:213-6. https://pubmed.ncbi.nlm.nih.gov/2950914

71. Wishner AJ, Teplitz ED, Goodman DS. Pityrosporum, ketoconazole, and seborrheic dermatitis. J Am Acad Dermatol. 1987; 17:140-1. https://pubmed.ncbi.nlm.nih.gov/2956294

72. McNeil. Nizoral (ketoconazole) 2% shampoo prescribing information. Fort Washington, PA; 2003 Oct.

73. Faergemann J. Treatment of serborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double blind study. Acta Derm Venereol. 1990; 70:171-2. https://pubmed.ncbi.nlm.nih.gov/1969208

74. Farr PM, Krause LB, Marks JM et al. Response of scalp psoriasis to ketoconazole. Lancet. 1985; 2:921-2. https://pubmed.ncbi.nlm.nih.gov/2865422

75. Ford GP, Farr PM, Ire FA et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol. 1984; 111:603-7. https://pubmed.ncbi.nlm.nih.gov/6093845

76. Green CA, Farr PM, Shusters. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987; 116:217-21. https://pubmed.ncbi.nlm.nih.gov/2950915

77. Cavwenbergh G, DeDoncker P, Schrootea P et al. Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. Int J Dermatol. 1986; 25:541. https://pubmed.ncbi.nlm.nih.gov/3533805

78. Lester M. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis. Cutis. 1995; 55:181-3. https://pubmed.ncbi.nlm.nih.gov/7634851

79. Greer DL. Topical treatment for moccasin-type tinea pedis. J Am Acad Dermatol. 1987; 16:554-6. https://pubmed.ncbi.nlm.nih.gov/3546420

80. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. https://pubmed.ncbi.nlm.nih.gov/9585862

81. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. https://pubmed.ncbi.nlm.nih.gov/8841739

82. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. https://pubmed.ncbi.nlm.nih.gov/8821170

83. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.

84. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. https://pubmed.ncbi.nlm.nih.gov/8642094

85. Reviewers’ comments (personal observations) on Sulconazole 84:04.08.

86. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. https://pubmed.ncbi.nlm.nih.gov/9515210

87. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. https://pubmed.ncbi.nlm.nih.gov/8821158

88. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. https://pubmed.ncbi.nlm.nih.gov/8642095

89. Bigardi AS, Pigatto PD, Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis. 1992; 26:281-2. https://pubmed.ncbi.nlm.nih.gov/1395584

90. Machet L, Vaillant L, Muller C et al. Contact dermatitis and cross-sensitivity from sulconazole nitrate. Contact Dermatitis. 1992; 26:352-3. https://pubmed.ncbi.nlm.nih.gov/1395603

91. Jones SK, Kennedy CTC. Contact dermatitis from tioconazole. Contact Dermatitis. 1990; 22:122-3. https://pubmed.ncbi.nlm.nih.gov/2138969

92. Baes H. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles. Contact Dermatitis. 1991; 24:89-93. https://pubmed.ncbi.nlm.nih.gov/1828223

93. Marren P, Powell S. Contact sensitivity to tioconazole and other imidazoles. Contact Dermatitis. 1992; 27:129-30. https://pubmed.ncbi.nlm.nih.gov/1395626

94. Stubb S, Heikkila H, Reitamo S et al. Contact allergy to tioconazole. Contact Dermatitis. 1992; 26:155-8. https://pubmed.ncbi.nlm.nih.gov/1387056

97. Lange DS, Richards HM, Guarnieri J et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 1998; 39:944-50. https://pubmed.ncbi.nlm.nih.gov/9843006

98. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995; 132:441-5. https://pubmed.ncbi.nlm.nih.gov/7718463

99. Danby FW, Maddin WS, Margesson LJ et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993; 29:1008-12. https://pubmed.ncbi.nlm.nih.gov/8245236

100. Go IH, Wientjens DP, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses. 1992; 35:103-5. https://pubmed.ncbi.nlm.nih.gov/1435847

101. Anon. Ketoconazole shampoo for dandruff. Med Lett Drugs Ther. 1994; 36:68. https://pubmed.ncbi.nlm.nih.gov/8022364

102. Bulmer AC, Bulmer GS. The antifungal action of dandruff shampoos. Mycopathologia. 1999; 147:63-65. https://pubmed.ncbi.nlm.nih.gov/10967964

103. Janssen Pharmaceutica. Nizoral (ketoconazole) 2% shampoo prescribing information. Piscataway, NJ; 1990 Jun.

104. McNeil Consumer Healthcare. Nizoral A-D (ketoconazole) 1% shampoo patient information. Fort Washington, PA; 2002 Dec 18.

105. Barrier Therapeutics, Inc. Xolegel (ketoconazole) 2% gel prescribing information. Princeton, NJ; 2006 Jul.

106. Stiefel Laboratories, Inc. Extina (ketoconazole) 2% foam prescribing information. Coral Gables, FL; 2007 Jun.

107. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006; 5:646-50. https://pubmed.ncbi.nlm.nih.gov/16865870

108. Swinyer LJ, Decroix J, Langner A et al. Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. Cutis. 2007; 79:475-82. https://pubmed.ncbi.nlm.nih.gov/17713152

109. Elewski BE, Abramovits W, Kempers S et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007; 6:1001-8. https://pubmed.ncbi.nlm.nih.gov/17966177

110. Teva Pharmaceuticals. Ketoconazole cream, 2% prescribing information. Sellersville, PA; 2005 Mar.

Medical Disclaimer